Vibativ

RSS

Withdrawn

This medicine's authorisation has been withdrawn

telavancin
MedicineHumanWithdrawn

Italian is available via eTranslation, the European Commission's machine translation service.

Translate to Italian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

The marketing authorisation for Vibativ has been withdrawn at the request of the marketing authorisation holder.

български (BG) (634.53 KB - PDF)

Visualizza

español (ES) (549.37 KB - PDF)

Visualizza

čeština (CS) (617.26 KB - PDF)

Visualizza

dansk (DA) (547.17 KB - PDF)

Visualizza

Deutsch (DE) (552 KB - PDF)

Visualizza

eesti (ET) (546.46 KB - PDF)

Visualizza

ελληνικά (EL) (639.48 KB - PDF)

Visualizza

français (FR) (550.8 KB - PDF)

Visualizza

hrvatski (HR) (1.06 MB - PDF)

Visualizza

italiano (IT) (548.98 KB - PDF)

Visualizza

latviešu (LV) (616.63 KB - PDF)

Visualizza

lietuvių (LT) (577.48 KB - PDF)

Visualizza

magyar (HU) (610.46 KB - PDF)

Visualizza

Malti (MT) (620.67 KB - PDF)

Visualizza

Nederlands (NL) (547.6 KB - PDF)

Visualizza

polski (PL) (615.07 KB - PDF)

Visualizza

português (PT) (549.16 KB - PDF)

Visualizza

română (RO) (576.09 KB - PDF)

Visualizza

slovenčina (SK) (617.05 KB - PDF)

Visualizza

slovenščina (SL) (568.91 KB - PDF)

Visualizza

suomi (FI) (547.15 KB - PDF)

Visualizza

svenska (SV) (548.33 KB - PDF)

Visualizza

Product information

български (BG) (1.66 MB - PDF)

Visualizza

español (ES) (972.49 KB - PDF)

Visualizza

čeština (CS) (1.37 MB - PDF)

Visualizza

dansk (DA) (998.7 KB - PDF)

Visualizza

Deutsch (DE) (1012.89 KB - PDF)

Visualizza

eesti (ET) (990.29 KB - PDF)

Visualizza

ελληνικά (EL) (1.7 MB - PDF)

Visualizza

français (FR) (1.03 MB - PDF)

Visualizza

hrvatski (HR) (1014.8 KB - PDF)

Visualizza

italiano (IT) (1.03 MB - PDF)

Visualizza

latviešu (LV) (1.41 MB - PDF)

Visualizza

lietuvių (LT) (1023.66 KB - PDF)

Visualizza

magyar (HU) (1.37 MB - PDF)

Visualizza

Malti (MT) (1.44 MB - PDF)

Visualizza

Nederlands (NL) (1016.54 KB - PDF)

Visualizza

polski (PL) (1.45 MB - PDF)

Visualizza

português (PT) (1004.82 KB - PDF)

Visualizza

română (RO) (1.06 MB - PDF)

Visualizza

slovenčina (SK) (1.39 MB - PDF)

Visualizza

slovenščina (SL) (1.39 MB - PDF)

Visualizza

suomi (FI) (983.01 KB - PDF)

Visualizza

svenska (SV) (1002.26 KB - PDF)

Visualizza

Íslenska (IS) (985.54 KB - PDF)

Visualizza

norsk (NO) (343.48 KB - PDF)

Visualizza
Latest procedure affecting product information:IAIN/0031
08/09/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (529.08 KB - PDF)

Visualizza

español (ES) (485.69 KB - PDF)

Visualizza

čeština (CS) (529.3 KB - PDF)

Visualizza

dansk (DA) (485.73 KB - PDF)

Visualizza

Deutsch (DE) (484.5 KB - PDF)

Visualizza

eesti (ET) (485.88 KB - PDF)

Visualizza

ελληνικά (EL) (528.76 KB - PDF)

Visualizza

français (FR) (484.57 KB - PDF)

Visualizza

hrvatski (HR) (492.6 KB - PDF)

Visualizza

italiano (IT) (503.04 KB - PDF)

Visualizza

latviešu (LV) (526.53 KB - PDF)

Visualizza

lietuvių (LT) (502.59 KB - PDF)

Visualizza

magyar (HU) (508.09 KB - PDF)

Visualizza

Malti (MT) (522.89 KB - PDF)

Visualizza

Nederlands (NL) (485.68 KB - PDF)

Visualizza

polski (PL) (523.08 KB - PDF)

Visualizza

português (PT) (485.04 KB - PDF)

Visualizza

română (RO) (509.16 KB - PDF)

Visualizza

slovenčina (SK) (540.33 KB - PDF)

Visualizza

slovenščina (SL) (507.44 KB - PDF)

Visualizza

suomi (FI) (488.95 KB - PDF)

Visualizza

svenska (SV) (485.59 KB - PDF)

Visualizza

Íslenska (IS) (484.25 KB - PDF)

Visualizza

norsk (NO) (469.96 KB - PDF)

Visualizza

български (BG) (700.28 KB - PDF)

Visualizza

español (ES) (613.31 KB - PDF)

Visualizza

čeština (CS) (1.19 MB - PDF)

Visualizza

dansk (DA) (614.54 KB - PDF)

Visualizza

Deutsch (DE) (617.65 KB - PDF)

Visualizza

eesti (ET) (617.52 KB - PDF)

Visualizza

ελληνικά (EL) (697.34 KB - PDF)

Visualizza

français (FR) (618.22 KB - PDF)

Visualizza

italiano (IT) (619.69 KB - PDF)

Visualizza

latviešu (LV) (660.48 KB - PDF)

Visualizza

lietuvių (LT) (634.24 KB - PDF)

Visualizza

magyar (HU) (647.41 KB - PDF)

Visualizza

Malti (MT) (768.5 KB - PDF)

Visualizza

Nederlands (NL) (613.46 KB - PDF)

Visualizza

polski (PL) (699.38 KB - PDF)

Visualizza

português (PT) (625.07 KB - PDF)

Visualizza

română (RO) (643.04 KB - PDF)

Visualizza

slovenčina (SK) (679.65 KB - PDF)

Visualizza

slovenščina (SL) (744.22 KB - PDF)

Visualizza

suomi (FI) (606.41 KB - PDF)

Visualizza

svenska (SV) (612 KB - PDF)

Visualizza

Product details

Name of medicine
Vibativ
Active substance
telavancin
International non-proprietary name (INN) or common name
telavancin
Therapeutic area (MeSH)
  • Pneumonia, Bacterial
  • Cross Infection
Anatomical therapeutic chemical (ATC) code
J01XA03

Pharmacotherapeutic group

Antibacterials for systemic use

Therapeutic indication

Vibativ is indicated for the treatment of adults with nosocomial pneumonia including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA).

Vibativ should be used only in situations where it is known or suspected that other alternatives are not suitable.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Authorisation details

EMA product number
EMEA/H/C/001240
Marketing authorisation holder
Theravance Biopharma Ireland Umited

Connaught House 1
Burlington Road
Fourth Floor
D04 C5Y6
Dublin 4
Ireland

Marketing authorisation issued
02/09/2011
Revision
10

Assessment history

This page was last updated on

Share this page